ACER - オペクサ・セラピュ―ティクス (Acer Therapeutics Inc.) オペクサ・セラピュ―ティクス

 ACERのチャート


 ACERの企業情報

symbol ACER
会社名 Acer Therapeutics Inc (オペクサ・セラピュ―ティクス)
分野(sector) Health Care   ヘルスケア
産業(industry) Major Pharmaceuticals  
業種 バイオテクノロジ―_メディカルリサ―チ   医療関連(Health Care)
概要 事業概要 オペクサ・セラピューティクス(Opexa Therapeutics Inc)はバイオ医薬品企業。同社は多発性硬化症(MS)などの疾患に対する治療の可能性のある個別化細胞療法の開発に従事する。それらの治療法は同社のT細胞技術をベースとしている。同社の主な製品候補であるTovaxinはベーラー医科大学(Baylor College of Medicine)からライセンスを受けた、MS治療用の臨床開発中の個別化T細胞治療ワクチンである。TcelnaはT細胞の免疫療法であり、IIb期臨床開発中の二次進行型MS(SPMS)治療用に使用される。Tcelnaは患者の疾患プロファイルに特に合わせる個人向け治療法である。TERMS研究は臨床分離症候群リスクの高いあるいは再発寛解型多発性硬化症(RRMS)を患っている150位患者を対象とする多中心の無作為プラセボ比較二重盲検臨床試験である。   オペクサ・セラピュ―ティクスは米国のバイオ医薬品会社。多発性硬化症(MS)など重篤な疾病、及び視神経脊髄炎などの免疫性疾患の自己免疫療法の開発に従事。独自に開発したT細胞技術に基づき、二次進行型MSや再発寛解型MSなどの治療薬の臨床開発段階にある。また、血液から単球由来幹細胞を生成するための成体幹細胞技術を開発。本社はテキサス州。   Acer is a pharmaceutical company focused on the acquisition, development and commercialization of therapies for serious rare and life-threatening diseases with significant unmet medical needs. Acer's pipeline includes four programs: ACER-001 (a taste-masked, immediate release formulation of sodium phenylbutyrate) for the treatment of various inborn errors of metabolism, including urea cycle disorders (UCDs) and Maple Syrup Urine Disease (MSUD); emetine hydrochloride, a host-directed therapy against a variety of infectious diseases, initially for the treatment of patients with COVID-19; EDSIVO™ (celiprolol) for the treatment of vascular Ehlers-Danlos syndrome (vEDS) in patients with a confirmed type III collagen (COL3A1) mutation; and osanetant for the treatment of induced Vasomotor Symptoms (iVMS). Each of Acer's product candidates is believed to present a comparatively de-risked profile, having one or more of a favorable safety profile, clinical proof-of-concept data, mechanistic differentiation and/or accelerated paths for development through specific programs and procedures established by the FDA.
本社所在地 One Gateway Center Suite 351 300 Washington St. Newton MA 02458 USA
代表者氏名
代表者役職名
電話番号
設立年月日 33298
市場名 NASDAQ Small Cap
ipoyear ―年
従業員数 6人
url www.acertx.com
nasdaq_url https://www.nasdaq.com/symbol/acer
adr_tso
EBITDA EBITDA(百万ドル) -16.45878
終値(lastsale) 28.37
時価総額(marketcap) 285203269.56
時価総額 時価総額(百万ドル) 282.99160
売上高 売上高(百万ドル) 0.00000
企業価値(EV) 企業価値(EV)(百万ドル) 274.64783
当期純利益 当期純利益(百万ドル) -16.51118
決算概要 決算概要 BRIEF: For the six months ended 30 June 2018 Acer Therapeutics Inc revenues was not reported. Net loss increased 36% to $8.8M. Higher net loss reflects General and administrative increase from $1.5M to $4.1M (expense). Basic Earnings per Share excluding Extraordinary Items decreased from -$1.01 to -$1.18.

 ACERのテクニカル分析


 ACERのニュース

   Here is What Hedge Funds Think About Acer Therapeutics Inc. (ACER)  2021/06/13 18:11:56 Insider Monkey
   Acer Therapeutics (ACER) Receives a Hold from Needham  2021/06/11 19:15:07 Smarter Analyst
Needham analyst Serge Belanger maintained a Hold rating on Acer Therapeutics (ACER) today. The companys shares closed last Friday at $3. The post Acer Therapeutics (ACER) Receives a Hold from Needham appeared first on Smarter Analyst .
   Acer Therapeutics plans clinical trial of Edsivo in connective-tissue disorder  2021/06/10 13:14:21 Seeking Alpha
   Acer Therapeutics Plans Clinical Trial for EDSIVO (celiprolol) Following Type B FDA Meeting  2021/06/10 12:30:00 Wallstreet:Online
Phase 3, randomized, double-blind, placebo-controlled, decentralized clinical trial estimated to take approximately 3.5 years to complete once fully enrolled FDA indicates agreement with submission of proposed protocol under a Special Protocol Assessment (SPA) with possible breakthrough designation NEWTON, Mass., June 10, 2021 (GLOBE NEWSWIRE) -- Acer Therapeutics Inc. (Nasdaq: ACER), a pharmaceutical
   Acer Therapeutics plans NDA submission for ACER-001 in Q3 2021  2021/05/25 12:48:36 Seeking Alpha
   Acer Therapeutics Enters Into ACER-001 Development Pact With Relief Therapeutics  2021/03/22 07:35:00 Benzinga
Relief Therapeutics Holding AG (OTCMKTS: RLFTF) and Acer Therapeutics Inc (NASDAQ: ACER) have entered into a Collaboration and …
   ACER Stock: The Merger Rumor That Has Acer Therapeutics Racing Higher  2021/03/15 15:02:49 InvestorPlace
Acer Therapeutics (ACER) stock is on the rise Monday as investors speculate about a possible merger with Relief Therapeutics.
   32 Stocks Moving in Monday's Pre-Market Session  2021/03/15 11:12:30 Benzinga
Gainers Acer Therapeutics Inc. (NASDAQ: ACER ) shares … Full story available on Benzinga.com
   Acer Therapeutics Reports Fourth Quarter and Full Year 2020 Financial Results and Provides Corporate Update - Acer Therapeutics  2021/03/01 21:12:28 Acer Therapeutics
NEWTON, MA –March 1, 2021 – Acer Therapeutics Inc. (Nasdaq: ACER), a pharmaceutical company focused on the acquisition, development and commercialization of therapies for serious rare and life-threatening diseases with significant unmet medical needs, today reported financial results for the fourth quarter and full year ended December 31, 2020 and provided an update on the […]
   Thinking about buying stock in Acer Therapeutics, Zomedica, Novan, Atossa Therapeutics, or Tellurian?  2021/01/25 14:31:00 PR Newswire
NEW YORK, Jan. 25, 2021 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for ACER, ZOM, NOVN, ATOS, and TELL. To see how InvestorsObserver's proprietary scoring system rates these stocks, view the InvestorsObserver's PriceWatch Alert by selecting the corresponding link….
   Acer Therapeutics Enters Into ACER-001 Development Pact With Relief Therapeutics  2021/03/22 07:35:00 Benzinga
Relief Therapeutics Holding AG (OTCMKTS: RLFTF) and Acer Therapeutics Inc (NASDAQ: ACER) have entered into a Collaboration and …
   ACER Stock: The Merger Rumor That Has Acer Therapeutics Racing Higher  2021/03/15 15:02:49 InvestorPlace
Acer Therapeutics (ACER) stock is on the rise Monday as investors speculate about a possible merger with Relief Therapeutics.
   32 Stocks Moving in Monday's Pre-Market Session  2021/03/15 11:12:30 Benzinga
Gainers Acer Therapeutics Inc. (NASDAQ: ACER ) shares … Full story available on Benzinga.com
   Acer Therapeutics Reports Fourth Quarter and Full Year 2020 Financial Results and Provides Corporate Update - Acer Therapeutics  2021/03/01 21:12:28 Acer Therapeutics
NEWTON, MA –March 1, 2021 – Acer Therapeutics Inc. (Nasdaq: ACER), a pharmaceutical company focused on the acquisition, development and commercialization of therapies for serious rare and life-threatening diseases with significant unmet medical needs, today reported financial results for the fourth quarter and full year ended December 31, 2020 and provided an update on the […]
   Thinking about buying stock in Acer Therapeutics, Zomedica, Novan, Atossa Therapeutics, or Tellurian?  2021/01/25 14:31:00 PR Newswire
NEW YORK, Jan. 25, 2021 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for ACER, ZOM, NOVN, ATOS, and TELL. To see how InvestorsObserver's proprietary scoring system rates these stocks, view the InvestorsObserver's PriceWatch Alert by selecting the corresponding link….

 関連キーワード  (バイオテクノロジ―_メディカルリサ―チ 米国株 オペクサ・セラピュ―ティクス ACER Acer Therapeutics Inc.)

 twitter  (公式ツイッターやCEOツイッターなど)